BR0016903A - Método de distribuição de drogas evitando ocorrência de efeitos colaterais adversos conhecidos ou suspeitos - Google Patents

Método de distribuição de drogas evitando ocorrência de efeitos colaterais adversos conhecidos ou suspeitos

Info

Publication number
BR0016903A
BR0016903A BR0016903-0A BR0016903A BR0016903A BR 0016903 A BR0016903 A BR 0016903A BR 0016903 A BR0016903 A BR 0016903A BR 0016903 A BR0016903 A BR 0016903A
Authority
BR
Brazil
Prior art keywords
drug
side effects
adverse side
patient
distribution method
Prior art date
Application number
BR0016903-0A
Other languages
English (en)
Inventor
Bruce A Williams
Joseph K Kaminski
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24787895&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0016903(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of BR0016903A publication Critical patent/BR0016903A/pt

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/20—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/60—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H70/00—ICT specially adapted for the handling or processing of medical references
    • G16H70/40—ICT specially adapted for the handling or processing of medical references relating to drugs, e.g. their side effects or intended usage
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S128/00—Surgery
    • Y10S128/92—Computer assisted medical diagnostics

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Primary Health Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Medical Treatment And Welfare Office Work (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

"MéTODO DE DISTRIBUIçãO DE DROGAS EVITANDO OCORRêNCIA DE EFEITOS COLATERAIS ADVERSOS CONHECIDOS OU SUSPEITOS". Divulgam-se nesta métodos melhorados para fornecer a um paciente precisando da droga, evitando ocorrer defeitos colaterais adversos conhecidos ou suspeitos causados pela droga. Os métodos são de um tipo no qual as prescrições para as drogas são preenchidas somente depois de um meio de armazenamento legível por computador ter sido consultado para garantir que prescrevente, farmácia, e paciente tenham sido apropriadamente registrados antes do paciente ser aprovado para receber a droga em questão. Provêem-se configurações onde os pacientes são designados a grupos de risco com base no risco de ocorrer efeitos colaterais em se tomando a droga, e certas informações adicionais, tal como pesquisas periódicas e testes de diagnóstico comprobatórios dos riscos correntes de se desenvolverem efeitos colaterais, serem obtidas antes de as prescrições para a droga serem aprovadas.
BR0016903-0A 2000-10-23 2000-10-24 Método de distribuição de drogas evitando ocorrência de efeitos colaterais adversos conhecidos ou suspeitos BR0016903A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/694,217 US6315720B1 (en) 2000-10-23 2000-10-23 Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug
PCT/US2000/029303 WO2002035440A1 (en) 2000-10-23 2000-10-24 Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug

Publications (1)

Publication Number Publication Date
BR0016903A true BR0016903A (pt) 2002-12-17

Family

ID=24787895

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0016903-0A BR0016903A (pt) 2000-10-23 2000-10-24 Método de distribuição de drogas evitando ocorrência de efeitos colaterais adversos conhecidos ou suspeitos

Country Status (11)

Country Link
US (9) US6315720B1 (pt)
EP (3) EP1330765A1 (pt)
JP (3) JP4727127B2 (pt)
CN (1) CN1425167A (pt)
AU (2) AU780486B2 (pt)
BR (1) BR0016903A (pt)
CA (1) CA2352629C (pt)
IL (1) IL150307A0 (pt)
MX (1) MXPA02006176A (pt)
NZ (1) NZ541736A (pt)
WO (1) WO2002035440A1 (pt)

Families Citing this family (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6045501A (en) * 1998-08-28 2000-04-04 Celgene Corporation Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug
US7115277B2 (en) * 1999-03-04 2006-10-03 Allergan, Inc. Method for enabling delivery of an active agent
US6588548B1 (en) * 1999-11-23 2003-07-08 Load King Manufacturing, Co. Pharmacy workstation and method of operation
US6315720B1 (en) 2000-10-23 2001-11-13 Celgene Corporation Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug
WO2002083865A2 (en) * 2001-04-13 2002-10-24 First Genetic Trust Methods and systems for managing informed consent processes
US20020187483A1 (en) * 2001-04-20 2002-12-12 Cerner Corporation Computer system for providing information about the risk of an atypical clinical event based upon genetic information
DE10142019A1 (de) * 2001-08-28 2003-03-20 Philips Corp Intellectual Pty Schaltungsanordnung zur Demodulation von Signalen
US7983848B2 (en) * 2001-10-16 2011-07-19 Cerner Innovation, Inc. Computerized method and system for inferring genetic findings for a patient
US7117158B2 (en) * 2002-04-25 2006-10-03 Bilcare, Inc. Systems, methods and computer program products for designing, deploying and managing interactive voice response (IVR) systems
USRE48890E1 (en) 2002-05-17 2022-01-11 Celgene Corporation Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation
US7968569B2 (en) 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
US20040019794A1 (en) * 2002-07-29 2004-01-29 Ahmad Moradi Method and system for delivering prescription medicine
US6871783B2 (en) * 2002-09-11 2005-03-29 William Kaafarani Method of dispensing medical prescriptions
US8404716B2 (en) 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US11116782B2 (en) 2002-10-15 2021-09-14 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US9740817B1 (en) 2002-10-18 2017-08-22 Dennis Sunga Fernandez Apparatus for biological sensing and alerting of pharmaco-genomic mutation
WO2004051549A2 (en) * 2002-12-02 2004-06-17 Allergan, Inc. Active agent delivery method
US7890341B2 (en) 2002-12-09 2011-02-15 Baxter International Inc. System and a method for providing integrated access management for peritoneal dialysis and hemodialysis
US7668730B2 (en) * 2002-12-17 2010-02-23 JPI Commercial, LLC. Sensitive drug distribution system and method
US8346482B2 (en) 2003-08-22 2013-01-01 Fernandez Dennis S Integrated biosensor and simulation system for diagnosis and therapy
US20050059709A1 (en) * 2003-09-15 2005-03-17 Meythaler Jay M. Treatment of a neuropathy with rapid release aminopyridine
JP4884220B2 (ja) * 2003-09-19 2012-02-29 タグ，エルエルシー 競争的処方薬および／または入札サービス提供者の選択方法
US8781857B2 (en) 2003-09-19 2014-07-15 Tag, Llc Method for competitive prescription drug and/or bidding service provider selection
US7558380B2 (en) * 2003-09-25 2009-07-07 Ateb, Inc. Methods, systems and computer program products for providing targeted messages for pharmacy interactive voice response (IVR) systems
US8029454B2 (en) 2003-11-05 2011-10-04 Baxter International Inc. High convection home hemodialysis/hemofiltration and sorbent system
US20050108051A1 (en) * 2003-11-07 2005-05-19 Andrew Weinstein Method of promoting patient adherence to a treatment regimen
US20050108053A1 (en) * 2003-11-14 2005-05-19 Jones Miles J.Jr. Interactive internet medical pharmaceutical prescribing system
US20050159985A1 (en) * 2003-11-21 2005-07-21 Bertram Carl T. System and method of stratifying intervention groups and comparison groups based on disease severity index scores and ranges
PL1836665T3 (pl) * 2004-11-19 2013-06-28 Glaxosmithkline Llc Sposób dostosowywania dozowania zmiennych dawek leków w produktach skojarzonych w celu indywidualizowania terapii
WO2006055928A2 (en) * 2004-11-19 2006-05-26 Smithkline Beecham Corporation Pharmaceutical product
US7885824B1 (en) * 2004-12-10 2011-02-08 Exela Pharmsci, Inc. Method and system for delivering medical therapies
US7281986B2 (en) * 2005-02-17 2007-10-16 Tolson Mark W Parallel putting device and method
JP2006285973A (ja) * 2005-03-09 2006-10-19 Fujimoto Corporation:Kk 薬剤管理システムおよびこれを用いた薬剤管理方法
US9235869B2 (en) * 2005-03-11 2016-01-12 Eric Greenman Method and system for tracking goods
CA2618141C (en) 2005-03-11 2015-09-01 Itd Holdings, L.L.C. Novel methods and systems for prescribing sample prescriptions
US7765110B1 (en) * 2005-03-29 2010-07-27 Exela Pharmsci, Inc. Method and system for delivering substitute medical therapies with restricted access
EP1872136B9 (en) 2005-04-04 2023-02-08 Biogen MA Inc. Methods and products for evaluating an immune response to a therapeutic protein
US20070219825A1 (en) * 2005-11-23 2007-09-20 Maetzold Derek J Method of managing and reducing side effects associated with exposure to a drug
US20070179806A1 (en) * 2006-02-01 2007-08-02 Knowlton Calvin H Medication therapy management process
LT2676967T (lt) 2006-02-28 2019-09-10 Biogen Ma Inc. Uždegiminių ir autoimuninių ligų gydymo būdai su natalizumabu
JP2009528640A (ja) * 2006-03-01 2009-08-06 タグ，エルエルシー 競合処方薬および／または入札サービスプロバイダ選択のための方法
BRPI0708392A2 (pt) 2006-03-03 2011-05-24 Elan Pharm Inc métodos de tratamento de um paciente com uma doença inflamatória ou autoimune com natalizumab e de uso de natalizumab para tratar um paciente com uma doença inflamatória ou autoimune
US7833724B2 (en) * 2006-03-20 2010-11-16 Teva Women's Health, Inc. Methods for comparing the immunogenicity of products and uses thereof
US8700430B2 (en) * 2006-07-17 2014-04-15 Walgreen Co. Optimization of a medication therapy regimen
US8478605B2 (en) 2006-07-17 2013-07-02 Walgreen Co. Appropriateness of a medication therapy regimen
US20080015893A1 (en) * 2006-07-17 2008-01-17 Walgreen Co. Identification of Inappropriate Medications In A Medication Therapy Regimen
US20110184747A1 (en) * 2006-08-09 2011-07-28 Carmen Bozic Method for distribution of a drug
US7729929B2 (en) * 2006-10-13 2010-06-01 Siemens Aktiengesellschaft Method and apparatus for delivery of medical items on an electronic prescription
US20080121743A1 (en) * 2006-11-29 2008-05-29 Fleckten Eric T System For Pneumatically Conveying Particulate Material
US20080201173A1 (en) * 2006-12-05 2008-08-21 Toyohiro Takehara Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated
US20100179824A1 (en) * 2007-06-21 2010-07-15 Muneya Fujimoto Management system for prescribing/dispensing medicine which may cause serious side effect
CA2705151A1 (en) 2007-11-08 2009-05-14 Glaxosmithkline Llc Medical product dispensing systems and methods
JP2011511782A (ja) 2008-02-12 2011-04-14 アボット・ラボラトリーズ 長期放出性ヒドロコドンアセトアミノフェンならびにその関連方法および用途
US20110166876A1 (en) * 2008-04-25 2011-07-07 Celgene Corporation Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated
US8112290B2 (en) * 2008-05-16 2012-02-07 Adolor Corporation Methods for delivering a drug to a hospital patient for short-term use while minimizing long-term use of the drug
US8386274B1 (en) 2008-09-17 2013-02-26 Mckesson Financial Holdings Limited Systems and methods for a prescription safety network utilizing eligibility verification transactions
PT2344677T (pt) * 2008-10-08 2017-07-13 Cambridge Entpr Ltd Métodos e composições para diagnóstico e tratamento de doença autoimune secundária a esclerose múltipla
EP2352479A4 (en) * 2008-11-05 2012-09-05 Stephen B Gold METHOD AND SYSTEM FOR MONITORING AND IMPROVING THE REGULATION AND DISTRIBUTION OF MEDICINAL PRODUCTS
WO2010065939A1 (en) 2008-12-05 2010-06-10 Indiana University Research & Technology Corporation Combination therapy to enhace nk cell mediated cytotoxicty
WO2010104841A2 (en) * 2009-03-09 2010-09-16 Celgene Corporation Device for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated and methods for use thereof
JP5752677B2 (ja) 2009-05-19 2015-07-22 セルジーン コーポレイション ４−アミノ−２−（２，６−ジオキソピペリジン−３−イル）イソインドリン−１，３−ジオンの製剤
US20110082867A1 (en) * 2009-10-06 2011-04-07 NeX Step, Inc. System, method, and computer program product for analyzing drug interactions
ES2666372T3 (es) 2009-10-11 2018-05-04 Biogen Ma Inc. Ensayos relacionados con anti-VLA-4
US20110141116A1 (en) 2009-12-16 2011-06-16 Baxter International Inc. Methods and apparatus for displaying flow rate graphs and alarms on a dialysis system
US11287423B2 (en) 2010-01-11 2022-03-29 Biogen Ma Inc. Assay for JC virus antibodies
PL2524060T3 (pl) 2010-01-11 2018-05-30 Biogen Ma Inc. Test wykrywający przeciwciała przeciwko wirusowi jc
US10911515B2 (en) 2012-05-24 2021-02-02 Deka Products Limited Partnership System, method, and apparatus for electronic patient care
US10242159B2 (en) 2010-01-22 2019-03-26 Deka Products Limited Partnership System and apparatus for electronic patient care
US20110313789A1 (en) 2010-01-22 2011-12-22 Deka Products Limited Partnership Electronic patient monitoring system
US10453157B2 (en) 2010-01-22 2019-10-22 Deka Products Limited Partnership System, method, and apparatus for electronic patient care
US11244745B2 (en) 2010-01-22 2022-02-08 Deka Products Limited Partnership Computer-implemented method, system, and apparatus for electronic patient care
US11881307B2 (en) 2012-05-24 2024-01-23 Deka Products Limited Partnership System, method, and apparatus for electronic patient care
US11210611B2 (en) 2011-12-21 2021-12-28 Deka Products Limited Partnership System, method, and apparatus for electronic patient care
US11164672B2 (en) 2010-01-22 2021-11-02 Deka Products Limited Partnership System and apparatus for electronic patient care
CA2832355A1 (en) * 2010-04-07 2012-10-13 Novacare Computer based system for predicting treatment outcomes
US8392219B1 (en) 2010-05-10 2013-03-05 Mckesson Financial Holdings Limited Systems and methods for streamlined patient enrollment for one or more healthcare programs
US10475140B2 (en) * 2010-05-13 2019-11-12 Axon Healthcare Services, Llc Prospective management process for medical benefit prescriptions
WO2011160042A2 (en) 2010-06-18 2011-12-22 Makoto Life Sciences, Inc. Prpk-tprkb modulators and uses thereof
CN110752000A (zh) 2011-03-10 2020-02-04 美迪生健康有限公司 改善医疗保健的方法、系统和程序
KR102292563B1 (ko) 2011-05-31 2021-08-24 바이오젠 엠에이 인코포레이티드 Pml의 위험을 판단하는 방법
EP2825989A4 (en) * 2012-03-16 2016-01-06 Alexion Pharma Inc METHODS OF DISPENSING MEDICATION INHIBITING COMPLEMENT TO PATIENTS RECEIVING COMPLEMENT INHIBITOR
JP2015529894A (ja) * 2012-07-24 2015-10-08 サイエンティフィックメッド・スウェーデン・アクチボラゲットＳｃｉｅｎｔｉｆｉｃｍｅｄ Ｓｗｅｄｅｎ Ａｂ いくつかの医薬品の化合物と一体化された通信ツールを用いた医薬品の臨床効果の向上
US9050302B2 (en) * 2013-03-01 2015-06-09 Jazz Pharmaceuticals Ireland Limited Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
EP3004334A4 (en) 2013-05-28 2016-12-21 Biogen Ma Inc METHODS OF EVALUATION RISK OF DEVELOPMENT OF PML
US10303853B2 (en) * 2014-01-10 2019-05-28 Iqvia Inc. System and method for data access in the distribution of limited distribution drugs
AU2015210999A1 (en) 2014-01-29 2016-07-21 Otsuka Pharmaceutical Co., Ltd. Device-based risk management of a therapeutic
ES2940302T3 (es) 2014-08-22 2023-05-05 Celgene Corp Métodos para tratar el mieloma múltiple con compuestos inmunomoduladores en combinación con anticuerpos
US10452815B2 (en) 2014-09-29 2019-10-22 Zogenix International Limited Control system for control of distribution of medication
US10496793B1 (en) 2014-12-15 2019-12-03 Mckesson Corporation Systems and methods for determining eligibility in a prescription safety network program
CN105139083A (zh) * 2015-08-10 2015-12-09 石庆平 一种药物上市后安全性再评价的方法及其系统
EP4293009A3 (en) 2015-12-22 2024-02-21 Zogenix International Limited Fenfluramine compositions and methods of preparing the same
CA3007673A1 (en) 2015-12-22 2017-06-29 Zogenix International Limited Metabolism resistant fenfluramine analogs and methods of using the same
US20180055789A1 (en) 2016-08-24 2018-03-01 Zogenix International Limited Formulation for inhibiting formation of 5-ht2b agonists and methods of using same
US20180075220A1 (en) * 2016-09-12 2018-03-15 National Health Coalition, Inc. Methods for Processing Submission and Fulfillment of Pharmaceutical Prescriptions in Real Time
US10600502B2 (en) * 2016-12-20 2020-03-24 Astrazeneca Uk Ltd. Systems and methods for dispensing a statin medication over the counter
US11034667B2 (en) 2017-01-09 2021-06-15 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
US11584733B2 (en) 2017-01-09 2023-02-21 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
US10093647B1 (en) 2017-05-26 2018-10-09 Celgene Corporation Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione dihydrate, compositions and methods of use thereof
US11456081B1 (en) 2017-07-20 2022-09-27 Jazz Pharmaceuticals, Inc. Sensitive drug distribution systems and methods
US11200971B2 (en) 2017-08-17 2021-12-14 Health2047, Inc. Secure token identification and medical rule-based authorization system
US10093649B1 (en) 2017-09-22 2018-10-09 Celgene Corporation Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione monohydrate, compositions and methods of use thereof
US10093648B1 (en) 2017-09-22 2018-10-09 Celgene Corporation Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione hemihydrate, compositions and methods of use thereof
US10682317B2 (en) 2017-09-26 2020-06-16 Zogenix International Limited Ketogenic diet compatible fenfluramine formulation
WO2019099868A2 (en) 2017-11-16 2019-05-23 C4 Therapeutics, Inc. Degraders and degrons for targeted protein degradation
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone
US11407723B2 (en) 2018-01-09 2022-08-09 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
EP3773576A4 (en) 2018-03-26 2021-12-29 C4 Therapeutics, Inc. Cereblon binders for the degradation of ikaros
WO2019204354A1 (en) 2018-04-16 2019-10-24 C4 Therapeutics, Inc. Spirocyclic compounds
CA3097335A1 (en) 2018-05-11 2019-11-14 Zogenix International Limited Compositions and methods for treating seizure-induced sudden death
CN108711444B (zh) * 2018-05-22 2022-03-25 广东工业大学 一种开具电子处方的方法和系统
EP3578561A1 (en) 2018-06-04 2019-12-11 F. Hoffmann-La Roche AG Spiro compounds
JP2021528735A (ja) * 2018-06-14 2021-10-21 アストラゼネカ・ユーケイ・リミテッドＡｓｔｒａＺｅｎｅｃａ ＵＫ Ｌｉｍｉｔｅｄ アンジオテンシンｉｉ受容体遮断薬医薬組成物による高血圧症の治療方法
US11227685B2 (en) 2018-06-15 2022-01-18 Xact Laboratories, LLC System and method for laboratory-based authorization of genetic testing
US11398312B2 (en) 2018-06-15 2022-07-26 Xact Laboratories, LLC Preventing the fill of ineffective or under-effective medications through integration of genetic efficacy testing results with legacy electronic patient records
US11380424B2 (en) 2018-06-15 2022-07-05 Xact Laboratories Llc System and method for genetic based efficacy testing
US11527331B2 (en) 2018-06-15 2022-12-13 Xact Laboratories, LLC System and method for determining the effectiveness of medications using genetics
WO2020051235A1 (en) 2018-09-04 2020-03-12 C4 Therapeutics, Inc. Compounds for the degradation of brd9 or mth1
WO2020132561A1 (en) 2018-12-20 2020-06-25 C4 Therapeutics, Inc. Targeted protein degradation
CN113557235A (zh) 2019-03-06 2021-10-26 C4医药公司 用于药物治疗的杂环化合物
US11189371B2 (en) 2019-04-30 2021-11-30 International Business Machines Corporation Systems and methods for adjusting medical treatment to reduce likelihood of prescription cascade
US11694810B2 (en) 2020-02-12 2023-07-04 MDI Health Technologies Ltd Systems and methods for computing risk of predicted medical outcomes in patients treated with multiple medications
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
US11600121B2 (en) 2020-07-21 2023-03-07 Unitedhealth Group Incorporated Systems and methods for conditional remote unlocking of identified containers
CN112258109B (zh) * 2020-10-22 2022-03-01 中山大学附属第三医院 一种安全高效的智能麻醉科药物配送收费方法及系统
USD1012481S1 (en) 2020-10-29 2024-01-30 Unitedhealth Group Incorporated Storage container assembly
WO2023178288A1 (en) 2022-03-17 2023-09-21 Azora Therapeutics, Inc. Companion diagnostics and strategies for treatment with an aryl hydrocarbon receptor agonist compound

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5974203A (en) * 1988-04-11 1999-10-26 Canon Kabushiki Kaisha Pattern recognition communication apparatus for transmitting and receiving image data
US5344832A (en) * 1990-01-10 1994-09-06 The Board Of Supervisors Of Louisiana University And Agricultural And Mechanical College Method for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hyperglycemia in vertebrates
US5299121A (en) 1992-06-04 1994-03-29 Medscreen, Inc. Non-prescription drug medication screening system
US5594637A (en) * 1993-05-26 1997-01-14 Base Ten Systems, Inc. System and method for assessing medical risk
US5660176A (en) 1993-12-29 1997-08-26 First Opinion Corporation Computerized medical diagnostic and treatment advice system
WO1996013790A1 (en) * 1994-10-28 1996-05-09 Advanced Health Med-E-Systems Corporation Prescription management system
US5845255A (en) 1994-10-28 1998-12-01 Advanced Health Med-E-Systems Corporation Prescription management system
US5758095A (en) 1995-02-24 1998-05-26 Albaum; David Interactive medication ordering system
JP4073976B2 (ja) * 1995-03-14 2008-04-09 株式会社東芝 薬発注システム
JPH08272882A (ja) * 1995-04-03 1996-10-18 Takashi Meguro 服薬指導支援システム
US5619991A (en) * 1995-04-26 1997-04-15 Lucent Technologies Inc. Delivery of medical services using electronic data communications
US6671563B1 (en) * 1995-05-15 2003-12-30 Alaris Medical Systems, Inc. System and method for collecting data and managing patient care
JPH0916064A (ja) * 1995-06-27 1997-01-17 Hitachi Ltd 患者教育システム
JP2914650B2 (ja) * 1995-09-29 1999-07-05 株式会社望星薬局 調剤支援システム及び医薬品等販売システム
US5832449A (en) 1995-11-13 1998-11-03 Cunningham; David W. Method and system for dispensing, tracking and managing pharmaceutical trial products
JP3025751B2 (ja) * 1995-11-16 2000-03-27 三洋電機株式会社 警告機能を備えた調剤料算定機
US6063026A (en) * 1995-12-07 2000-05-16 Carbon Based Corporation Medical diagnostic analysis system
US5924074A (en) * 1996-09-27 1999-07-13 Azron Incorporated Electronic medical records system
US6131090A (en) * 1997-03-04 2000-10-10 Pitney Bowes Inc. Method and system for providing controlled access to information stored on a portable recording medium
AU8472098A (en) 1997-06-19 1999-01-04 Promedicus Systems, Inc. System for providing recommendations to physicians and for managing health care data
JPH1131189A (ja) * 1997-07-09 1999-02-02 Saitama Medeikomu Kk 薬剤指導書の作成システム
WO1999010829A1 (en) * 1997-08-22 1999-03-04 Deka Products Limited Partnership Health care system and method for physician order entry
JP3251225B2 (ja) * 1998-02-26 2002-01-28 勲 長澤 病棟情報システム
US6014631A (en) 1998-04-02 2000-01-11 Merck-Medco Managed Care, Llc Computer implemented patient medication review system and process for the managed care, health care and/or pharmacy industry
US6045501A (en) 1998-08-28 2000-04-04 Celgene Corporation Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug
US6128620A (en) 1999-02-02 2000-10-03 Lemed Inc Medical database for litigation
JP3029829B2 (ja) * 1999-02-04 2000-04-10 株式会社望星薬局 医薬品等販売システム
US6561978B1 (en) * 1999-02-12 2003-05-13 Cygnus, Inc. Devices and methods for frequent measurement of an analyte present in a biological system
GB9904585D0 (en) * 1999-02-26 1999-04-21 Gemini Research Limited Clinical and diagnostic database
JP2000276537A (ja) * 1999-03-23 2000-10-06 Triad Japan Kk 薬剤師カウンセリング支援システム及びコンピュータに薬剤師カウンセリング支援を行わせるためのプログラムを記録した媒体
US6202923B1 (en) * 1999-08-23 2001-03-20 Innovation Associates, Inc. Automated pharmacy
US6315720B1 (en) 2000-10-23 2001-11-13 Celgene Corporation Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug
CA2352619C (en) 2001-07-06 2008-02-19 Robert C. Rajewski Mud tank cleaning system
US7668730B2 (en) 2002-12-17 2010-02-23 JPI Commercial, LLC. Sensitive drug distribution system and method
US20060129433A1 (en) 2004-12-10 2006-06-15 Phanesh Koneru Method and system for delivering high risk medical therapies

Also Published As

Publication number Publication date
US20130046554A1 (en) 2013-02-21
AU2005201675B2 (en) 2008-03-13
US20060224052A1 (en) 2006-10-05
WO2002035440A1 (en) 2002-05-02
AU780486B2 (en) 2005-03-24
US20020052543A1 (en) 2002-05-02
US20120316894A1 (en) 2012-12-13
JP4727127B2 (ja) 2011-07-20
US8315886B2 (en) 2012-11-20
JP2009233326A (ja) 2009-10-15
US6561977B2 (en) 2003-05-13
US20110082707A1 (en) 2011-04-07
AU1437201A (en) 2002-05-06
US20050176768A1 (en) 2005-08-11
NZ541736A (en) 2006-12-22
JP5244268B2 (ja) 2013-07-24
US20040152959A1 (en) 2004-08-05
EP2226740A1 (en) 2010-09-08
US20030149345A1 (en) 2003-08-07
AU2005201675A1 (en) 2005-05-12
CA2352629A1 (en) 2002-04-23
US6869399B2 (en) 2005-03-22
MXPA02006176A (es) 2002-12-05
IL150307A0 (en) 2002-12-01
US6755784B2 (en) 2004-06-29
EP1330765A1 (en) 2003-07-30
EP1970827A1 (en) 2008-09-17
US6315720B1 (en) 2001-11-13
US7141018B2 (en) 2006-11-28
CA2352629C (en) 2015-02-03
US7959566B2 (en) 2011-06-14
JP2006209801A (ja) 2006-08-10
US8626531B2 (en) 2014-01-07
CN1425167A (zh) 2003-06-18
JP2004512617A (ja) 2004-04-22

Similar Documents

Publication Publication Date Title
BR0016903A (pt) Método de distribuição de drogas evitando ocorrência de efeitos colaterais adversos conhecidos ou suspeitos
Sepehrmanesh et al. Therapeutic effect of adjunctive N-acetyl cysteine (NAC) on symptoms of chronic schizophrenia: A double-blind, randomized clinical trial
Culligan et al. The mesocolon: a prospective observational study
BRPI0720906B8 (pt) método e sistema para planejar um procedimento restaurativo dental e sistema de computador para realizar o método
Morgado et al. Cut‐off scores in MMSE: a moving target?
Spaeth et al. Cellular mechanisms of plasmalemmal sealing and axonal repair by polyethylene glycol and methylene blue
Thompson et al. Hyperphosphatasia with seizures, neurologic deficit, and characteristic facial features: Five new patients with Mabry syndrome
BR0211915A (pt) Execução de aplicação habilitada para teste
Levitan et al. Impact of oxLDL on cholesterol‐rich membrane rafts
Hur et al. An anatomic study of the quadratus plantae in relation to tendinous slips of the flexor hallucis longus for gait analysis
Goubier et al. Transfer of two motor branches of the anterior obturator nerve to the motor portion of the femoral nerve: an anatomical feasibility study
Reuther et al. Effect of return to overuse activity following an isolated supraspinatus tendon tear on adjacent intact tendons and glenoid cartilage in a rat model
Won et al. Topography of the arteries supplying the masseter muscle: using dissection and Sihler's method
Gonzaga et al. HLA alleles in Brazilian patients with fissured tongue
Pera et al. Evaluation of internal and external hexagon connections in immediately loaded full‐arch rehabilitations: A within‐person randomized split‐mouth controlled trial with a 3‐year follow‐up
Zhao et al. Hidden talents: Poly (I: C)‐induced maternal immune activation improves mouse visual discrimination performance and reversal learning in a sex‐dependent manner
Atzmony et al. Inflammatory linear verrucous epidermal nevus (ILVEN) encompasses a spectrum of inflammatory mosaic disorders
Pan et al. Alternative lymphatic drainage routes from the lateral heel to the inguinal lymph nodes: anatomic study and clinical implications
Kawabe et al. Intrahippocampal D-cycloserine improves MK-801-induced memory deficits: radial-arm maze performance in rats
Su et al. Ultrasound‐guided injection of botulinum toxin in a patient with omohyoid muscle syndrome: A case report
Miller et al. The long‐term effect of oromaxillofacial trauma on the function of the temporomandibular joint
Gholizadeh et al. Pemphigus vulgaris associated with rheumatoid arthritis in a patient not taking penicillamine
Liu et al. Profiling of innervations of mimetic muscles in fresh human cadavers using a modified Sihler's technique
Hufeland et al. Blood supply in the bicipital groove: A histological analysis
Nagashima et al. Paraparetic Guillain‐Barré syndrome: Extending the axonal spectrum

Legal Events

Date Code Title Description
B15K Others concerning applications: alteration of classification

Free format text: A CLASSIFICACAO ANTERIOR ERA: G06F 19/00

Ipc: G06Q 50/24 (2012.01)

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM OS ARTIGOS 8O COMBINADO COM ART.13 E ART. 10 DA LPI

B12B Appeal against refusal [chapter 12.2 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: G06F 19/00 (2018.01), G06Q 50/22 (2018.01), G16H 1